Record Details
Field | Value |
---|---|
Title | Extended-release Naltrexone for Alcohol and Opioid Dependence: A Meta-Analysis of Healthcare Utilization Studies |
Names |
Hartung, Daniel
(creator) McCarty, Dennis (creator) Fu, Rongwei (creator) Wiest, Katharina (creator) Chalk, Mady (creator) Gastfriend, David R. (creator) |
Date Issued | 2014-08 (iso8601) |
Abstract | Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over six months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone. |
Genre | Article |
Topic | Extended-release Naltrexone |
Identifier | Hartung, D. M., McCarty, D., Fu, R., Wiest, K., Chalk, M. & Gastfriend, D. R. (2014). Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. Journal of Substance Abuse Treatment, 47(2), 113-121. doi: 10.1016/j.jsat.2014.03.007 |